Seaside Therapeutics LLC

It was old home week at Keeping Track, featuring the return of two previously withdrawn new drug applications and, in what is now a regular occurrence, two immuno-oncology approvals. Even the new fili

Alcobra CEO Yaron Daniely admits that drug development for attention deficit hyperactivity disorder (ADHD) is a "road well-traveled," but says his Tel Aviv, Israel-based company is forging a new path

High levels of unmet medical need and the staggering direct and indirect costs of mental health disorders – $2.5 trillion worldwide in 2010, according to the National Institutes of Health ’s Nati

Finally armed with the tools to investigate the onset of fragile X syndrome, the most common genetic form of intellectual disability, researchers have elucidated the intracacies of its mechanism and a